Blood Res.  2013 Mar;48(1):68-69. 10.5045/br.2013.48.1.68.

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome

• Jung CW

• KMID: 2270732
• DOI: http://doi.org/10.5045/br.2013.48.1.68

Abstract

No abstract available.

MeSH Terms

Primary Myelofibrosis
Pyrazoles
Transplants
Pyrazoles

Reference

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366:799–807. PMID: 22375971.

2. Vannucchi AM, Passamonti F, Al-Ali HK, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in comfort-II, a phase 3 study comparing the safety and efficacy of ruxolitinib with best available therapy (BAT). Blood. 2012; 120:634. (abst 802).

3. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012; 120:1202–1209. PMID: 22718840.

4. Carniti C, Gimondi S, Vaccaroli R, et al. Inhibition of JAK1/JAK2 is more effective than inhibition of JAK3 in protecting mice from acute graft-versus-host disease (aGVHD) by significantly decreasing alloreactive CD4+ T-cells. Blood. 2012; 120:702. (abst 2997).

5. Ciurea SO, Sadegi B, Wilbur A, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol. 2008; 141:80–83. PMID: 18324970.